EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence

Ramya Padmavathy Radha Krishnan, Monika Dzidowska, Danni Zheng, Zoie Shui-Yee Wong, Nicholas A Buckley, Jacques Eugene Raubenheimer

European Child & Adolescent Psychiatry · 2025

DOI: 10.1007/s00787-025-02771-0 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Child & Adolescent Psychiatry, 2025. Verfasst von Ramya Padmavathy Radha Krishnan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, The University of Sydney, RC Mills Building Room 107, Sydney, NSW, 2006, Australia. ramya.radhakrishnan@sydney.edu.au. Hauptthemen laut MEDLINE: Antipsychotic Agents, Mental Disorders, Metabolic Syndrome, Cardiovascular Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre for Research Excellence in Medicines Intelligence (MI-CRE), University of Sydney.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antipsychotics are known to cause cardiovascular and metabolic adverse effects, but there is less evidence for their use off-label, especially in children and adolescents. Such treatments may be administered over long durations. We conducted a systematic review to examine the cardiometabolic adverse effects of prolonged antipsychotic treatment in children and adolescents with non-psychotic disorders. We searched for randomised clinical trials and observational studies lasting for a year or more, examining the adverse outcomes of weight gain, hyperglycaemia, dyslipidaemia, hypertension, metabolic syndrome, ischaemic heart disease, and thrombosis. There were no randomised trials, and 15 observational studies involved 114,141 participants with mean age of 10.9 years (range of means 4.3–14.9 years). Twelve antipsychotics were covered but the majority (12 studies, 80%) examined risperidone. Using the vote counting method, long-term antipsychotic treatment was associated with weight gain (91.6% studies, n = 12), hyperglycaemia (100%, n = 6), dyslipidaemia (66.6%, n = 6), and metabolic syndrome (100%, n = 2). Hypertension was demonstrated in only one study (25%, n = 4), and none examined ischaemic heart disease or thrombosis. Studies exhibited moderate to high methodological quality. Prolonged exposure to antipsychotics during childhood may be associated with several metabolic adverse effects that could have long-term health impacts. Longer-term studies on a wider range of agents are required to clarify risks and develop appropriate strategies to mitigate them. Antipsychotic prescribing for children should be assessed on an individual basis, after weighing the benefits of therapy against the harms that may arise. Children need to be monitored for these metabolic effects, and early intervention is essential if adverse effects are severe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsMental DisordersMetabolic SyndromeCardiovascular DiseasesMetabolic DiseasesHumansChildAdolescentChild, Preschool

Stichwörter der Autor:innen

AntipsychoticCardiovascular and metabolic adverse effectsChildren and adolescentsNon-psychotic conditionsOff-label disordersSafety outcomes

Substanzen

Antipsychotic Agents

Autor:innen und Institutionen

  • Faculty of Medicine and Health, The University of Sydney, RC Mills Building Room 107, Sydney, NSW, 2006, Australia. ramya.radhakrishnan@sydney.edu.au.
  • Faculty of Medicine and Health, The University of Sydney, RC Mills Building Room 107, Sydney, NSW, 2006, Australia.
  • Graduate School of Public Health, St. Luke's International University, Tokyo, Japan.

Förderung

  • Centre for Research Excellence in Medicines Intelligence (MI-CRE)
  • University of Sydney

Zitieren

APA

Radha Krishnan, R. P., Dzidowska, M., Zheng, D., Wong, Z. S., Buckley, N. A., & Raubenheimer, J. E. (2025). Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence. European Child & Adolescent Psychiatry. https://doi.org/10.1007/s00787-025-02771-0

Vancouver

Radha Krishnan RP, Dzidowska M, Zheng D, Wong ZS, Buckley NA, Raubenheimer JE. Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence. European Child & Adolescent Psychiatry. 2025. doi:10.1007/s00787-025-02771-0

BibTeX
@article{RadhaKrishnan2025,
  author = {Radha Krishnan, Ramya Padmavathy and Dzidowska, Monika and Zheng, Danni and Wong, Zoie Shui-Yee and Buckley, Nicholas A and Raubenheimer, Jacques Eugene},
  title = {Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence},
  journal = {European Child & Adolescent Psychiatry},
  year = {2025},
  doi = {10.1007/s00787-025-02771-0}
}
Kostenlos starten →